Bezlotoxumab and Clostridioides difficile Infection

If C. difficile infection cure is achieved at 3 months, recurrence at 12 months is comparable between standard-of-care treatment and standard of care with bezlotoxumab.

In the manufacturer-funded Modify I and II clinical trials, the addition bezlotoxumab, a Clostridioides difficile toxin B human monoclonal antibody, to standard-of-care (SoC) therapy for C. difficile infection (CDI) resulted in comparable clinical cure rates but lower recurrence rate at 12 weeks, with an acceptable safety profile. The addition of actoxumab, a C. difficile toxin A human monoclonal antibody, alone or in combination with bezlotoxumab, did not provide additional benefit. There was a concern that the bezlotoxumab infusion might be just delaying the CDI recurrences, given the drug's long half-life of 19 days.

In the long-term observational follow-up of patients from MODIFY II, investigators have now evaluated participants with a s…

Reviewing Author

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Bezlotoxumab and Clostridioides difficile Infection

Topics

Reviewing Author